Bio­gen, Ei­sai re­leas­es four-year da­ta on ad­u­canum­ab; EMA stamps Ei­dos' aT­TR ther­a­py with or­phan des­ig­na­tion

→ Af­ter an at­tempt to res­ur­rect faith in their Alzheimer’s drug BAN2401, us­ing a small sub­set of pa­tients from a close­ly watched Phase II tri­al on Thurs­day, Bio­gen $BI­IB and Ei­sai fol­lowed up on Fri­day with long term da­ta from a Phase I ex­ten­sion study of its oth­er ex­per­i­men­tal Alzheimer’s drug, ad­u­canum­ab. The Phase Ib tri­al now has four years of re­sults, and an analy­sis of da­ta sug­gests ad­u­canum­ab played a role in a con­tin­ued slow­ing of clin­i­cal de­cline in pa­tients over 36 months and 48 months, Bio­gen said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER